stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Net income
Relay Therapeutics, Inc.'s net income for fiscal 2025 was −$276.5M, compared with −$337.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$286.0M. Over the past ten years it has ranged from −$363.9M (fiscal 2021) to $0.00 (fiscal 2017); the current reading is higher than 56% of that period. Relay Therapeutics, Inc. ranks 556th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$276.5M | — |
| FY2024 | −$337.7M | — |
| FY2023 | −$342.0M | — |
| FY2022 | −$290.5M | — |
| FY2021 | −$363.9M | — |
| FY2020 | −$52.4M | — |
| FY2019 | −$75.3M | — |
| FY2018 | −$48.8M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$83.7M | — |
| Mar 2026 | −$73.3M | — |
| Dec 2025 | −$54.9M | — |
| Sep 2025 | −$74.1M | — |
| 25 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| TNGX Tango Therapeutics, Inc. compare | −$123.7M |
| ABCL AbCellera Biologics Inc. compare | −$164.7M |
| PBLS Parabilis Medicines, Inc. compare | −$170.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$197.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$220.5M |
| IRON Disc Medicine, Inc. compare | −$245.9M |
| RLAY Relay Therapeutics, Inc. | −$286.0M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RLAY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement